Large patient impact Genomic Health has a proven track record with Oncotype DX tests used to guide treatment decisions for more than 750,000 cancer patients across 90+ countries, indicating a broad, established base for upsell or cross-sell of expanded genomic test menus and services.

Expanding test portfolio Recent launches such as Oncotype SEQ Liquid Select and ongoing expansion from tissue-based to liquid biopsy tests create opportunities to pitch integrated genomic intelligence solutions and companion diagnostics for multiple cancer types and stages.

Strategic partnerships Past collaborations and asset movements with MDxHealth and the significant Exact Sciences relationship (including the sale and potential mergers) signal a favorable environment for alliance-based sales, licensing, or co-developed diagnostics with large channel partners.

Global reach With headquarters in Redwood City and international presence in Geneva, plus multi-country usage, there is potential to tailor region-specific value propositions, navigate payer considerations, and expand in emerging markets where precision oncology adoption is growing.

Data-driven care The Oncotype IQ Genomic Intelligence Platform positions Genomic Health to offer advanced analytics and predictive insights across the cancer care journey, enabling selling points around treatment optimization, reduced overtreatment, and cost-effective care pathways to payers and health systems.